Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Study of Human Microbiota in Healthy and Pathological Conditions (MicroSP)

2. marts 2018 opdateret af: Istituto Ortopedico Galeazzi

The aim of the present study is to characterize the bacterial composition (microbiota) colonizing to the human body in different physio - pathological conditions (lifestyle, motor activity, surgical operations, probiotic and prebiotic consumption, antibiotic therapies, chemotherapeutic therapies), nervous and musculoskeletal diseases, gastrointestinal and metabolic disorders , oral and vaginal diseases, etc.). In particular, they will be investigate:

  • the changes in the bacterial abundance
  • the potential microbial interactions with the human host
  • the microbial networks describing on the bacterial interactions within a specific composition of the human microbiota

Studieoversigt

Status

Ukendt

Intervention / Behandling

Detaljeret beskrivelse

The main objective of this study is to deepen the knowledge about the bacterial communities associated to the human organism. In particular, the present study aims to evaluate how the microbiota (intestinal, cutaneous, vaginal, nasal, bronchial, breast milk, salivary, oral, etc.) is subject to quantitative and qualitative changes consequently to different events involving the human host. The project trys to highlight which microorganisms may be involved in the onset or progression of certain pathological condition, as well as to identify which bacterial genera can be more subject to variations due to specific non-pathological events.

Secondary objectives of this study are:

  • To define a "healthy microbiome", that is to understand which are the main bacteria that commonly compose the human microbiome in physiological conditions, differentiating it from that present in certain pathological conditions.
  • To characterize the physiological effects that bacterial changes of the human microbiota have on the host.
  • To evaluate whether the use of probiotics, prebiotics, dietary and nutritional factors, cosmetics, and oral, nasal, vaginal, or pharmacological therapies of any kind can influence the microbial network of the human microbiota associated to different body districts.

Undersøgelsestype

Observationel

Tilmelding (Forventet)

30

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • MI
      • Milan, MI, Italien, 20161
        • IRCCS Istituto Ortopedico Galeazzi

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

For each cohoort 15 healthy subjects will be enrolled (controls), for a total of 90 subjects.

The study involves the recruitment of 180 subjects (90 pathological and 90 healthy and recruited

Beskrivelse

Inclusion Criteria:

  • subjects suffering from neurological/behavioral diseases;
  • subjects suffering of bone diseases;
  • subjects affected of dysmetabolic / or endocrine disorders;
  • subjects with physical activities at a competitive level;
  • subjects affected of gastrointestinal disorders;
  • subjects with prolonged antibiotic therapies and undergoing surgery

Exclusion Criteria:

  • no use of probiotics in the month prior the sampling;
  • no use of antibiotics in the month prior the sampling;
  • no consumption of yogurt in the month prior the sampling;

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

Kohorter og interventioner

Gruppe / kohorte
Intervention / Behandling
Neurological and behavioral disorders
Subjects with neurological or behavioral disorders such as Tourette syndrome are enrolled.
To evaluate the effects of a specific event (i.e. surgical operation) or therapy (i.e antibiotic treatment) over time;
Andre navne:
  • Probiotics, dietary factors, cosmetics and adjuvants
Subjects affected by bone diseases
Subjects affected by bone diseases such as infective osteomyelitis or osteoporosis are enrolled.
To evaluate the effects of a specific event (i.e. surgical operation) or therapy (i.e antibiotic treatment) over time;
Andre navne:
  • Probiotics, dietary factors, cosmetics and adjuvants
Dysmetabolic and/or endocrine disorders
Patients with endocrine disorders, such as thyroid disfunctions, or with metabolic disorders, including diabetes mellitus,are enrolled.
Subjects performing agonistic activity
Subjects performing physical activity at agonistic level are enrolled.
Gastroenteric disorders
Subjects affected by gastric and/or enteric disorders are enrolled.
Prolonged antibiotic therapy
Patients subjected to prolonged antibiotic therapies and undergone a variety of surgical procedures are enrolled.
To evaluate the effects of a specific event (i.e. surgical operation) or therapy (i.e antibiotic treatment) over time;
Andre navne:
  • Probiotics, dietary factors, cosmetics and adjuvants
Healthy subjects
Subjects without any known ongoing disease are enrolled.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Bacterial abundances calculated by mean of Operational Taxonomic Unit (OTU) count
Tidsramme: Up to 24 weeks
It is a measure of the bacterial amount
Up to 24 weeks

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Chao's indices estimated on the total OTU amount
Tidsramme: Up to 24 weeks
It is a measure of bacterial diversity
Up to 24 weeks
Simpson's index (D) estimated on the total OTU amount
Tidsramme: Up to 24 weeks
It is a measure of bacterial diversity
Up to 24 weeks
Shannon's index estimated on the total OTU amount
Tidsramme: Up to 24 weeks
It is a measure of bacterial diversity
Up to 24 weeks
The OTU abundances will be used to calculate an adjacency matrix based on the Spearman's correlation coefficient (rs) among different bacterial genus
Tidsramme: up to 24 weeks
It is a measure of strength of linear association between different bacterial genera
up to 24 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Lorenzo Drago, Prof., IRCCS Galeazzi Orthopedic Institute, Milan, Italy

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

12. juni 2017

Primær færdiggørelse (Faktiske)

31. juli 2017

Studieafslutning (Forventet)

31. december 2019

Datoer for studieregistrering

Først indsendt

15. februar 2018

Først indsendt, der opfyldte QC-kriterier

2. marts 2018

Først opslået (Faktiske)

9. marts 2018

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

9. marts 2018

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

2. marts 2018

Sidst verificeret

1. februar 2018

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Andre undersøgelses-id-numre

  • MiscoSP

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Antibiotic therapy

Abonner